Mauritskliniek intends to join Corius

Amsterdam, 21 July 2022 – Our portfolio company Mauritskliniek intends to join Corius. Mauritskliniek provides healthcare services in dermatology, varicose veins, proctology, skin therapy and medical-cosmetic care. The Mauritskliniek is located in Amsterdam, The Hague, Nijmegen, Utrecht and Veldhoven. Corius is the largest network of dermatology and phlebology practices in Germany and Switzerland.

By acquiring Mauritskliniek, Corius geographically expands its European healthcare offerings to the Netherlands. Both the services and vision of Mauritskliniek are perfectly consistent with those of  Corius.

Mauritskliniek intends to join Corius in the third quarter of 2022, after potential approval of the  Nederlandse Zorgautoriteit (NZa).

About Corius

Corius is a network of dermatology and phlebology practices. Doctors and partners of Corius deliver the highest level of quality and apply the most modern technology. An absolute passion for the job and patients is pivotal in the way of working. Corius offers their patients holistic and individual treatments, whereby in-house expert knowledge is shared across cross-clinics and colleagues. Employees follow additional education and trainings throughout. Corius has 32 practices and employs 139 doctors and 615 employees. About 450.000 patients are treated each year. www.corius.de

About Mauritskliniek

Mauritskliniek is a specialized clinic for dermatology, treatment for varicose veins and medical-cosmetic care. After the acquisition of Kliniek Veldhoven in 2020, the range of cosmetic-care has been further expanded. The clinics are known for high quality and a pleasant way of working. Their values are personal, clear and well organized. The clinics offer both insured and uninsured care. Customer satisfaction is rated with 8.6/10 points, according zorgkaartnederland.nl. www.maurtiskliniek.nl

About Holland Capital

Over the past 40 years, Holland Capital has responsibly and successfully invested in over more than 150 SME-companies. With a clear investment strategy Holland Capital is active in the attractive growth markets of Healthcare and Technology. Holland Capital’s experienced and committed investment team aims to establish an open, sustainable, and professional relationship with the companies they invest in, with the common goal of achieving growth. Holland Capital is backed by a broad network of successful healthcare entrepreneurs in the relevant growth markets.

Holland Capital invests in terminal home care organization Attenza

Holland Capital invests in terminal home care organization Attenza

Amsterdam, 15 June 2023 – Holland Capital invests in Attenza, a care organization specialized in offering terminal palliative care at home. With the investment Attenza can execute its ambitious growth path. Palliative terminal care The aging population in the...

Holland Capital invests in House of Clouds and Synobsys

Holland Capital invests in House of Clouds and Synobsys

Amsterdam, May 9th, 2023 - Holland Capital invests in House of Clouds and Synobsys, two renowned players in the field of Intelligent Automation. Holland Capital's investment ensures that their growth ambitions can be realised. Intelligent Automation Intelligent...

Holland Capital sells its stake in Valori

Holland Capital sells its stake in Valori

Amsterdam/Utrecht, 4 April 2023 – Holland Capital sells its stake in Valori to Cerios. Valori believes that embedding integral quality into IT systems is crucial to allow carefree innovation. The Quality Assurance and Test Consultants of Valori build towards the...

YOEP joins forces with De Praktische GGZ

YOEP joins forces with De Praktische GGZ

Amsterdam, 14 March 2023 – Our portfolio company YOEP will collaborate with De Praktische GGZ. The combination, made possible by Holland Capital, will further create an organisation with a wide range of both youth assistance and mental healthcare. De Praktische GGZ...

Amsterdam
Krijn Taconiskade 426
1087 HW Amsterdam
+31 (0) 20 311 94 11

 

Düsseldorf
Inselstraße 34
40479 Düsseldorf
+49 (0) 211 43 63 69 01